GILD and those in power are in the same social networks. They will make sure GILD gets a share of the pie. They'll slice and dice the data from their trials to determine a specific segment of patients that may benefit, but that likely wouldn't have needed rem in the first place. They'll leave it up to other drugs to help the riskier groups.

This is why its so important that CYDY show that their drug helps mild to moderate patients as well. But this could put a target on CYDY's back. GILD will not easily let a small company steal their meal without a fight.